Sanofi, Mylan Spar Over Surescripts Ruling In EpiPen Fight

By Matthew Perlman (January 24, 2020, 6:27 PM EST) -- Mylan told a Kansas federal judge on Friday that Sanofi is wrong to argue that a recent ruling in the Federal Trade Commission's monopolization case against Surescripts supports allegations that Mylan violated antitrust law in an effort to maintain the dominance of its EpiPen....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!